Search

Oxaliplatin

[A797] Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.[L47316] … [A796,A797] This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination.

Chromium gluconate

Chromium nicotinate

Clobetasol propionate

[A190936] Clobetasol Propionate was granted FDA approval on 27 December 1985.[L11809]

Degarelix

Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.

Pegfilgrastim

There are several pegfilgrastim biosimilars (Fulphila, Pelgraz or Lapelga, Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by Health Canada, European Union (EU), and FDA that are approved to … [A187607] First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.

Cystine

A covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.

Nicoboxil

Nicoboxil has been investigated for the treatment of Acute Low Back Pain, where it is typically considered an effective and safe therapeutic option. … nonivamide topical analgesic medication being used since the 1950s, recent studies demonstrate continued interest in the medication(s) given its demonstrated efficacy, safety, and capability to be used as an

Ripretinib

Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.

Levamlodipine

[A188940] Levamlodipine was granted FDA approval on 19 December 2019.[L10833] … [L10833] This medication was first marketed in Russia and India before being granted FDA approval.